Our findings indicate that anti-PD1 therapy uniquely induces the expression of inhibitory receptors on TILs when used against neuroblastoma tumors with induced MMR deficiency, but this is not the case with anti-CTLA4 therapy. This evidence concerns the gene CTLA4 and mismatch repair cancer syndrome 1.